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The cellular and molecular requirements for /3-cell damages in an immune-mediated toxin-
induced insulin-dependent diabetes mellitus have been studied in the model of multiple low-dose
streptozotocin-induced diabetes in rats and mice. It was found that strain-related susceptibility to
diabetes induction correlated with a higher level of IL-2, IFN-y, and TNF-ce production, whereas
such differences were not observed when IL-1 and NO production by macrophages were
analyzed; elimination of immunoregulatory RT6+T cells that increases IFN-y production,
enhances susceptibility to MLD-STZ-induced diabetes; mercury-induced Th-2 cells down-
regulated the disease; IFN-y-mediated macrophage activation to produce proinflammatory
cytokines rather than NO is an important event in early diabetogenic effects of invading
macrophages; inhibition of IL-1 activity downregulates diabetes induction; and generation ofNO
in/3 cells appears to be important for diabetogenic effects. Taken together, data indicate that
MLD-STZ diabetes is induced by Th-1 lymphocytes that secrete soluble effector molecules that
activate macrophages and promote destruction of/3 cells possibly by both nitric oxide and
nonnitric oxide-mediated mechanisms.
Keywords: Insulin-dependent diabetes mellitus, nitric oxide, RT6 T cells, interferon-y, tumor necrosis
factor, interleukin- 1, interleukin- inhibitor
INTRODUCTION
Autoimmune diseases are characterized by a failure of
self-tolerance leading the immune system to attack
and destroy endogenous tissues. In insulin-dependent
diabetes mellitus (IDDM), hyperglycemia is the
outcome of a pathological process leading to inflam-
matory reaction with endothelial-cell activation and
accumulation of macrophages, helper, and cytotoxic
T cells. The role of T cells in the pathogenesis of
IDDM was suggested by (a) their presence in the
mononuclear cell infiltrates in the pancreatic islets
(Huang et al., 1995), (b) the effects of cyclosporin in
delaying disease onset (Bougneres et al., 1988), (c)
observation of the transfer of diabetes by transplanta-
tion of bone marrow of diabetes patients to an
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immunodepressed nondiabetic recipient (Lampeter et
al, 1993), and (d) the recurrence of insulitis in
pancreatic grafts in IDDM patients (Sibley et al.,
1985). However, the target of autoimmune response is
not fully understood. In fact, the list of candidate
antigens is still increasing, including molecules recog-
nized by T cells and those identified by auto-
antibodies. Most of these autoantigens are not
restricted to /3 cells, indicating that microenvir-
onmental factors at the level of the target tissue may
be important for the autodestructive process.
Macrophage Influx Is an Early Event in Diabetes
Induction
Macrophages are found to be the first cells to infiltrate
the islets in at least two experimental models of
IDDM: Multiple low-dose streptozotocin (MLD-
STZ) induced diabetes in mice (Kolb-Bachofen et al.,
1988) and rats (Lukic et al., 1991) (Figure la) and
Bio-Breeding (BB) diabetes-prone rats (Hanenberg et
al., 1989). Obviously, it is important to distinguish
between the role of macrophages as antigen-present-
ing cells in inducing islet-specific immunity and their
role as effector cells directly inducing dysfunction
and /3-cell damage. There is ample evidence to
support a role of macrophages as effector cells in
experimental models of IDDM. Macrophages are
cytotoxic to pancreatic/3 cells in vitro (Appels et al.,
1989). Administration of macrophage toxic agents
like silica prevents diabetes in BB rats (Oschilewski
et al., 1985). Transfer of diabetes in NOD mice is
prevented by blockade of adhesion-promoting recep-
tor on macrophages (Hutchings et al., 1990).
Additionally, the finding of heavy macrophage infil-
tration and acute onset in IDDM patients provides
indication for macrophage role in human disease
(Lemmark et al., 1995). It was reported that free-
oxygen-radical production from activated macro-
phages is increased in diabetes-prone BB rats before
the appearance of inflammatory lesions in the islet
(Brenner et al., 1993). It was therefore of interest to
study the correlates of macrophage recruitment into
the islet during MLD-STZ -induced diabetes.
IFN-y Enhances Diabetes Induction
Interferon-y plays an essential role in the recruitment
of inflammatory cells into delayed-type hypersensi-
tive lesions (Issekutz et al., 1988). Rabinovitch et al.
(1996) have compared cytokine gene expression in
islet-infiltrating cells of diabetic-prone BB rats, rats
protected from diabetes by early treatment with CFA,
and diabetes-resistant rats. They found that mRNA
expression of T-helper 1 (Th- 1)-type cytokines, IFN-
y, and IL-2 by infiltrating cells correlates with/g-cell-
destructive insulitis and IDDM. Furthermore, it was
found that destruction of B cells in syngeneic islets
transplanted into NOD mice is promoted by cells
producing Th-1-type cytokines and prevented by cells
producing IL-4 and IL-10 (Suarez-Pinzon et al.,
1996).
We studied the susceptibility to MLD-STZ-induced
diabetes in two strains of rats, Albino Oxford (AO)
and Dark August (DA), which differ in the level of
IL-2 (Lukic et al., 1987) and IFN-yproduction (Arsov
et al., 1995). We have previously demonstrated that
these differences correlated with the susceptibility to
the experimental allergic encephalomyelitis (EAE)
(Vukmanovic et al., 1990; Arsov et al, 1995). High
IL-2 and IFN-y producer EAE-susceptible DA rats
are highly susceptible to MLD-STZ-induced diabetes
(Figure 1) and low Th-1 cytokine producer and EAE-
resistant AO rats are also resistant to diabetes
induction (Lukic et al., 1991; Shahin et al., 1995).
This may imply that the level of IFN-y required for
optimal stimulation of effector cells in diabetes
induction is not achieved in MLD-STZ-treated AO
rats. Additionally, there is evidence that exogenous
IFN-y may easily enhance diabetes in NOD mice
(Campbell et al., 1991). Therefore, we have tested
whether the additional availability to IFN-y in vivo
would overcome the resistance to the induction of
MLD-STZ in AO rats. Indeed, when AO rats were
given 50,000 i.u. of IFN-y i.v. on days 3, 5, 8, and 10
after the beginning of MLD-STZ regimen (20 mg/kg
on days 0 to 4), the resistance to MLD-STZ-induced
diabetes was abrogated. It also accelerated the disease
development in DA rats (Figures lb and lc). Thus, it
appears that strain differences in susceptibility toIMMUNE EFFECTOR MECHAIIISMS IN DIABETES 121
FIGURE MLD-STZ diabetes in susceptible DA rats. (A) Early influx of macrophages: ED-1 positive cells by day 6 after disease
induction (PAP). (B) Difuse mononuclear infiltrate in the islet by day 31 after MLD-STZ treatment (HE). (C) CD4 cells in and around the
islet by day 10 after MLD-STZ-diabetes induction (W3/25 mabs, PAP). (D) Mononuclear cell infiltrate in the islets 10 days after inititation
of MLD-STZ + IFN-T treatment (see text) (HE).
toxin-triggered autoimmune diabetes does not only
correlate with the level of IFN-T production, but may
be also manipulated by in vivo administration of this
cytokine.
It had been shown that diabetes-prone BB rats
suffer from a recessively inherited T-cell lymphope-
nia and failure to express RT6 autoantigen on T cells
of lymph node and spleen (Greiner et al., 1987). It
appears that RT6 can generate activation signals that
result in enhanced expression of a cytokine-receptor
molecule (Rigby et al., 1996). We have analyzed the
quantitative participation of RT6 cells in the peri-
pheral T-cell pool of MLD-STZ-induced diabetes-
resistant AO and susceptible DA rats. The results122 M.L. LUKI et al.
clearly indicated that RT6 cells were significantly
more numerous in both CD4 and CD8 T-cell
subsets in AO rats. To test whether these findings
were relevant for the strain-related differences in
susceptibility to MLD-STZ-induced diabetes, we
pretreated rats with five daily injections (1 ml i.p.) of
anti-RT6 monoclonal antibody containing 6A5
hybridoma culture supernatants prior to the induction
of diabetes. The treatment decreased the number of
RT6 T-cells for about 80% in both strains (Pravica et
al., 1993). Lymphoid cells derived from AO rats in
comparison with DA cells produced significantly less
IL-2 and IFN-y in response to Con A stimulation in
vitro and depletion of RT6 cells enhanced the level
of cytokine production. These increases were fivefold
in AO rats for both cytokines. However, although the
production of IFN-y was enhanced by anti-RT6
antibody, the level reached after the treatment was
three times lower than in normal DA rats. This
treatment converted AO rats from resistant to diabetes
to mildly diabetic and had a clear enhancing effect in
susceptible DA rats.
In studying the role of IFN-y in the induction of
MLD-STZ, we attempted to manipulate the suscept-
ibility to the disease by modulating Th-l-Th-2
balance in DA rats. To this end, we used a Th-
2-enhancing procedure, the administration of multiple
subtoxic doses of mercuric chloride (HgCI2). It had
been shown that this treatment may lead in suscept-
ible mouse strains to nonorgan-specific autoimmune
disease characterized by increased serum level of
IgG1 and IgE antibodies and by the occurrence of
antinuclear autoantibodies and immune-complex-
mediated glomerulonephritis (A1-Balaghi et al.,
1996). It appears that mercury-induced IgG1 and IgE
antibody synthesis is T-helper cell-dependent and
requires a Th-2-derived cytokine, IL-4 (A1-Balaghi et
al., 1996). Pretreatment with HgCI2 protected suscept-
ible rats against experimental autoimmune uveor-
etinitis induced by immunization with the retinal S
antigen. This effect was related to the preferential
activation of Th-2 cells and IL-4 production (Saoudi
et al., 1993) and indicates that activation of Th-2 cells
protects against Th-1-dependent autoimmune disease.
Therefore, we have treated MLD-STZ-susceptible
DA rats with HgC12 (3 1 mg/kg/day in 2-day
intervals) during MLD-STZ-diabetes induction. This
treatment had a long lasting protective effect (Figure
2). Depletion of CD8 T cells in vivo did not alter
susceptibility to MLD-STZ diabetes in DA rats and
protective effect of mercury (Stosic-Grujicic et al.,
1996). The results are compatible with the notion that
activation of Th-2 cells downregulated MLD-STZ-
diabetes induction possibly by affecting the avail-
ability of interferon-y at the level of the target
tissue.
Macrophage-Derived Proinflammatory Cytokines
Induce/-Cell Damage
The analysis of the mechanisms by which macro-
phages elicit its diabetogenic effect is increasingly
focused in recent years. Thus, it had been reported
that macrophage cytotoxicity toward islet cells in
vitro is related to macrophage generation of nitric
oxide (NO) (Kr6ncke et al., 1991a). However, it was
also shown that macrophage-produced NO is not
specifically cytotoxic for/3 cells in the islet (Kr6ncke
et al., 1991b). It was therefore postulated and shown
in vitro that macrophages exert their effector function
via their production of inflammatory cytokines such
as interleukin-1 (IL-1) and tumor necrosis factor
(TNF). Indeed, several recent studies have demon-
strated marked expression of IL-1, TNF-c, IFN-% IL-
6 RNAs, and/or proteins in the mononuclear infiltrates
of islets in NOD mice and BB rats (reviewed in
Mandrup-Poulsen, 1996).
In vitro studies have also indicated that IL-1 exerts
a/3-cell selective toxic effect (Bendtzen et al., 1986).
It was thereafter demonstrated that IL-1 reduces /3-
cell DNA content (Sandler et al., 1987), induces DNA
damage (Delaney et al., 1993), and reduces /g-cell
viability (Bolaffi et al., 1994). Although the in vitro
studies have demonstrated that IL-1 is a most
important cytokine mediating -cell damage, TNF-c
and IFN-y potentiate the action of IL-1 (Eizirik,
1988). Additionally, it had been shown that resident
monocytes in normal rat islets stimulated ex vivo with
LPS will produce sufficient quantity of proinflamma-
tory cytokines to markedly inhibit insulin secretionIMMUNE EFFECTOR MECHANISMS IN DIABETES 123
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FIGURE 2 MLD-STZ-induced diabetes in mercury-treated rats. Rats were pretreated with HgC12 (1 mg/kg b.w. in 2-day intervals) from
days -6 to 2 in relation to MLD-STZ-diabetes induction (20 mg/kg b.w. for five consecutive days).
(Corbett and McDaniel, 1995). It appears that NO, a
free radical formed during the oxidation of L-arginine
to L-citrulline, in a reaction catalyzed by inducible
NO synthase (iNOS) (Knowles and Moncada, 1994),
mediates a number of the effects of IL-1, including
the inhibitory effect of IL-1 on/3 cells (Corbett et al,
1991; Delaney et al., 1993). Most recently, Dunger et
al. (1996) demonstrated that in vitro treatment of
islets with TNF-ce or IFN-T on their own or in
combination inhibited glucose-stimulated insulin
secretion in a dose-dependent manner. These effects
of TNF-ce and IFN-T appeared also to be associated
with increased generation of NO. With respect to NO
generation, inhibition of glucose-induced insulin
secretion and induction of DNA damage in rat islets
TNF-ce and IFN-T individually exert effects largely
similar to those of IL-1.
The validity of the hypothesis that proinflammatory
cytokines and nitric oxide generation play a pivotal
role in autoimmune-mediated/3-cell damage may be,
to a certain extent, tested in the animal models of
IDDM. To this end, we have analyzed the effect of
TNF-ce, and IL-1 production and availability in the
induction MLD-STZ diabetes in mice and rats. We
compared the production of IL-1, TNF-ce, and NO by
activated macrophages derived from rats susceptible
or resistant to the induction of diabetes. It was found
that recombinant rat IFN-y or LPS + IFN-y stimula-
tion led to severalfold higher production of TNF-ce in
the cultures derived from DA rats (Table I). These
differences were not seen in the production of IL-1
and NO.
IL-1 Inhibitors Suppress Development of
Diabetes
Studies on the impact of systemic IL-1 administration
in spontaneous disease models of IDDM have pro-
duced different results. The aggravating effects of
high doses were observed in BB rats (Wilson et al.,
1990) whereas low doses exerted protective effects in
NOD mice (Jacob et al., 1990). It should be noted that
IL-1 may induce downregulatory cytokine IL-10,
which in turn may (Tilag et al., 1995) prevent the124 M.L. LUKI( et al.
TABLE Interferon-y, Interleukin-2, Tumor Necrosis Factor-a and Nitric Oxide Production by Mononuclear Cells of MLD-STZ
Diabetes-Susceptible (DA) and-Resistant (AO) Rats
Producer cells Mediator DA AO
Con A (5 /zg/ml) stimulated IL-2 34.36 11.57
lymph node cells
Con A (5/zg/ml) stimulated RT6- lymph
node cells
LPS (1 /xg/ml) stimulated
peritoneal macrophages
IFN-y (400/zg/ml) stimulated
peritoneal macrophages
IFN-y 315.19 18.46
IL-2 97.54 56.6
IFN-y 302.13 97.3
TNF-ce 3022.9 1431.3
NO 51.6 65.9
TNF-ce 1981.2 58.9
NO 49.9 61.3
Note: IFN-y and IL-2 were determined in supernatants of Con A (5/xg/ml) stimulated lymph node cell (5 105) culture (0.2 ml) at 48 hr.
Results are expressed as pg/ml. TNF-a (pg/ml) and NO (/xM/1) were determined in supernatants of peritoneal macrophage cultures at 24 hr.
of stimulation.
TABLE II Effect of IL-1 Inhibitor on the Development of Insulitis, Islet-Cell Damage, Hyperglycemia, and NO Production
Animal Treatment Cellular Plasma Area of
no. infiltration Islet-cell damage glucose iNOS + cells
score Vacuolization Picnosis Score (mm/l) within an islet
1. STZ + media + + + + 17.2 >50%
2. STZ + media ++ ++ + ++ 22.8 >50%
3. STZ + media ++ ++ + ++ 19.3 >50%
4. STZ + IL-1 INH + + 8.4 <5%
5. STZ + IL-1 INH + + 9.6 <5%
6. ST + IL-1 INH + + 6.8 <5%
Note: Based on a minimum of 10 islets per pancreas evaluated mophometrically 25 days after the induction of MLD-STZ diabetes (4 40
mg/kg b.w.) in CBA mice. Beginning with the thrid day of STZ injections, mice were given 10 daily i.p. injections of ml of 50-100 kD
IL-INH enriched fraction (Stosic and Lukic, 1992) or RPMI-1640. Rabit anti-mouse iNOS was kindly provided by Dr. C. Nathan and applied
as described in Stenger et al. (1994).
onset of diabetes, as shown in NOD mice (Pennline et
al., 1994). Protection from diabetes with soluble IL-1
receptor was observed in NOD mice (Nicoletti et al.,
1994).
We have analyzed the effect of IL-1 inhibition on
MLD-STZ-induced diabetes in male CBA mice. Mice
injected i.p. with five consecutive daily doses of 40
mg/kg of STZ developed delayed hyperglycemia 10
to 20 days after the completion of the treatment.
Sustained hyperglycemia was observed during the
next 2 months and mononuclear cell infiltration was
present in the islets of the diseased mice. In order to
inhibit IL-1 activity during the induction phase of this
model, mice received five consecutive days of STZ in
conjunction with 10 daily injections of unfractionated
rat IL-1 inhibitor (Stosic and Lukic, 1992). Treatment
with IL-1 INH started on the third day of STZ and
continued until day 12. Elevated levels of glucose in
blood in control injected animals were seen by day 10
after completion of STZ treatments and remained
high for at least an additional 2 months. This delayed
onset of diabetes was characterized with inflamma-
tory infiltrates as well as the vacuolization and
picnosis of islet cells (Table II). By contrast, mice
receiving STZ and IL-1 INH did not show significant
increases in plasma glucose. In agreement with theIMMUNE EFFECTOR MECHANISMS IN DIABETES 125
diabetic status, there was also moderate reduction in
the numbers of infiltrating cells and significant
decrease in destruction of the islet cells. The effect of
rat glucocorticoid-induced IL-1 INH on the onset of
diabetes was compared with that of human IL-1Ra.
Human IL-1Ra was also protective, although some-
what less than the preparation of IL-1 INH. Partial
protective effect of IL-IRa was observed in a repeated
experiment and lasted until the end of the experi-
ments, that is, 7 weeks after the induction of diabetes
(Lukic and Stosic, 1993; and to be published). At this
time, histologic examination revealed only mild
mononuclear infiltration at the periphery of islets in
contrast to the widespread insulitis in STZ-treated
mice. Thus, both inhibitors of IL-1 activity, that is, rat
macrophage-derived glucocorticoid-induced IL-1
INH or human IL-1Ra, diminished the induction of
STZ-induced diabetes in mice as evaluated by
functional and morphological criteria.
Nitric Oxide Synthesis and/3-Cell Damage
There is evidence that the deleterious effects of
cytokines on islet/3 cells are mediated via induction
of NO (Corbett and McDaniel., 1992; Reimers et al.,
1996). Inhibitors ofNO production protect against IL-
1/3-induced/3-cell damage in vitro (Bergmann et al.,
1992). We (Lukic et al., 1991) and Kolb et al. (1991)
have shown that the administration of Na-mono
methyl-L-arginine (NMMA), an inhibitor of NO
synthesis, modulates the response to the induction of
MLD-STZ diabetes in mice. These findings are
recently extended by the observations that NMMA
significantly reduced the incidence of IDDM in
diabetes-prone BB rats (Lindsay et al., 1995; Wu,
1995). However, the source of production of NO
during diabetes development was not identified in any
of the preceding studies. Early studies have proposed
that activated macrophages infiltrating the islets are
likely to be an important source of NO (Kroncke et
al., 1991b). However, the fact that macrophage
cytotoxicity to islet cells via macrophage NO produc-
tion is not specific for/3 cells (Kr6ncke et al., 1991a)
indicates that macrophages exert their effector func-
tion via other soluble mediators, for example, proin-
flammatory cytokines. Indeed, Southern et al. (1990)
have shown that IL-1 with potentiating effects of
TNF-ce causes NO generation in rat islet cells. An
explanation for the /3-cell selective toxicity of IL-1
was provided with the finding of expression of
cytokine iNOS, identical to macrophage iNOS in/3
cells (Karlsen et al., 1995) and that this enzyme was
not induced in purified non-/3 cells (Strandell et al,
1995). We concluded that the IFN-y + TNF-c + IL-1
in situ effect on NO generation in/3 cells (Table II)
rather than macrophage-derived NO may be respons-
ible for the higher susceptibility of DA rats to MLD-
STZ-induced diabetes.
Finally, it was recently argued that NO production
may be neither a necessary nor sufficient precondition
for cytokine-induced /3-cell destruction (Mandrup-
Poulsen, 1996). For example, although the combina-
tion of IL-1/3, TNF-ce, and IFN-y caused marked NO
production in human islets (Corbett et al., 1993), the
inhibitors of NO synthase apparently did not prevent
the suppressive effects of the cytokines on insulin
release and content (Eizirik et al., 1994). Thus,
additional mediators or the facilitation of other
apoptosis-inducing pathways may be involved.
Indeed, Dunger et al. (1996) have found that TNF-ce
and IFN-y inhibit insulin secretion and cause DNA
damage in unweaned-rat islets, but that as cytokine
concentrations increase, nonnitric oxide-mediated
events predominate. Finally, in an attempt to directly
analyze NO involvement in MLD-STZ-induced dia-
betes, we attempted to induce disease in "knock-out"
mice lacking iNOS (Wel et al., 1995). Both (129
MF1) homozygous mutant mice as well as hetero-
zygous control mice were susceptible to high-dose
STZ-induced diabetes but resistant to induction of
diabetes with four daily doses of 40 mg STZ. The
relative resistance to MLD-STZ-induced diabetes was
observed even when five daily injections of STZ were
applied. However, at several weeks after the induction
of the disease, glycemia was significantly higher in
heterozygous than in iNOS-deficient mice (unpub-
lished). The experiments studying the relevance of
iNOS deficiency in MLD-STZ-susceptible mice126 M.L. LUKI et al.
should give the final answer concerning the contribu-
tion of NO generation in disease induction (our work
in progress).
CONCLUDING COMMENTS
There is a growing body of evidence that Th-l-type
CD4 T cells participate in diabetes induction by
producing cytokines that promote destruction of the/3
cells. When this hypothesis is tested in mouse and rat
strains susceptible or resistant to induction of MLD-
STZ-induced diabetes, the following conclusions
could be derived: (1) Strain-related susceptibility to
diabetes induction correlated with higher levels of IL-
2, IFN-y, and TNF-ce production, whereas such
differences were not observed when IL-1 and NO
production by macrophages were analyzed. (2) Elim-
ination of immunoregulatory RT6 T cells that
increases IFN-y production enhances susceptibility to
MLD-STZ-induced diabetes. (3) It appears that IFN-
y-mediated macrophage activation to produce proin-
flammator cytokines rather than NO is an important
event in early diabetogenic effects of invading
macrophages. (4) Inhibition of IL-1 activity down-
regulates diabetes induction. (5) Generation ofNO in
/3 cells appears to be important in the development of
MLD-STZ-induced diabetes, but the extent of nitric
oxide involvement and participation of nonnitric
oxide-mediated mechanisms in vivo remains to be
studied.
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